BioCryst Pharmaceuticals Inc
(NAS:BCRX)
$
7.82
-0.37 (-4.52%)
Market Cap: 1.62 Bil
Enterprise Value: 2.18 Bil
PE Ratio: 0
PB Ratio: 0
GF Score: 75/100 BioCryst Pharmaceuticals Inc at Bank of America Healthcare Conference Transcript
May 10, 2022 / 03:00PM GMT
Release Date Price:
$8.6
(+2.75%)
Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst
Okay, everybody. Good morning. Thanks for joining us. I'm Tazeen Ahmad, I'm one of the senior to biotech analyst here at Bank of America. It is our pleasure to welcome you to the BofA Healthcare Conference back live after 3 years, since forever. And I've covered BioCryst for probably the longest time I've covered any company. So I think it's fitting that BioCryst be first on the agenda for us.
Gentlemen, good morning.
Jon P. Stonehouse
BioCryst Pharmaceuticals, Inc. - CEO, President & Executive Director
Good morning.
Tazeen Ahmad;Jon P. Stonehouse
BofA Securities, Research Division - MD in Equity Research & Research Analyst;BioCryst Pharmaceuticals, Inc. - CEO
So Jon and Charlie. I think everybody knows you, but I'll let you guys introduce yourselves. And maybe, Jon, you could give us a 2-minute overview of the company, and then we can go into general Q&A that works.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot